Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Artepharm Global to Market TCM-Based Malaria Drug

publication date: Apr 20, 2010
Artepharm Global Corp. formed a joint venture with a similarly named China company, Artepharm Co. Ltd. (Artepharm China), to market a malaria drug. Artepharm China is a Guangzhou based biopharma whose malaria drug, Artequick®, produced $1.5 million of revenue in 2009. Under the terms of the JV, Artepharm Global will acquire the global marketing rights and hold the global patents for Artequick, as well as retain all the sales revenues in exchange for 40 million shares of Artepharm Global’s stock. More details...

Stock Symbol: (OTCBB: ARGC)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China